Oral Abstract Session:
169b. Late Breaker Oral Abstracts
Saturday, October 5, 2013: 10:30 AM-12:00 PM
Room: The Moscone Center: 102 (Gateway Ballroom)

Learning Objectives:

It is assumed that participants know or are familiar with the general principles of the epidemiology, pathogenesis, prevention, and therapy of infectious diseases.  At the conclusion of this session, participants will be knowledgeable about:

  • cutting-edge information on the recognition, clinical presentation, pathogenesis, prevention, and therapy of evolving or newly emerging infectious diseases
  • the most recent threats to human health in the infectious disease field

Target Audience: vaccinologists, scientists, researchers, public health practitioners, pharmacists, nurses, microbiologists, members-in-training, medical students and residents, lab personnel, investigators, infectious diseases physicians, infectious diseases pediatricians, infection preventionists, hospital epidemiologists, hospital administrators, HIV specialists, HIV clinicians, health care workers, fellows, epidemiologists, clinicians, academicians

Topical Category: A. Antimicrobial agents including antibacterial, antiviral and antifungal drugs

Tracks: Pediatric ID, Investigative ID, HIV-STD-TB, Global ID, Epidemiology and Infection Control, Adult ID

Moderator:  Keith Klugman, MD, PhD, FIDSA, Bill & Melinda Gates Foundation

Presentations:

10:30 AM
Six months versus six weeks of oral valganciclovir for infants with symptomatic congenital cytomegalovirus (CMV) disease with and without central nervous system (CNS) involvement: Results of a Phase III, randomized, double-blind, placebo-controlled, multinational study
David W. Kimberlin, MD, FIDSA ; Penelope Jester, MSN BSN ; Pablo J. Sanchez, MD, FIDSA ; Amina Ahmed, MD ; Ravit Arav-Boger ; Sunil Sood, MD ; Charles Woods, MD, MS, FIDSA, FSHEA ; Negar Ashouri, MD ; Janet A. Englund, MD, FIDSA ; Benjamin Estrada, MD ; Richard Jacobs, MD ; Jose R. Romero, MD ; Suzanne Whitworth, MD ; Mark J Abzug, MD ; Mary T. Caserta, MD ; Sandra Fowler, MD ; Jorge Lujan-Zilbermann, MD ; Gregory Storch, MD, FIDSA ; Robert W. Tolan Jr., MD ; Roberta Debiasi, MD ; Jin-Young Han ; April Palmer, MD ; Leonard Weiner, MD ; Joseph Bocchini Jr., MD, FAAP ; Penelope Dennehy, MD ; Adam Finn, MD, PhD ; Paul Griffiths, MD ; Kathleen Gutierrez, MD ; Natasha Halasa, MD MPH ; James Homans, MD ; Andi L. Shane, MD, MPH, MSc ; Mike Sharland, MD ; Kari Simonsen, MD ; John A. Vanchiere, M.D., Ph.D. ; Inmaculada Aban, PhD ; Edward Acosta, PharmD ; Richard Whitley, MD, FIDSA ; Marian Michaels, MD, MPH

10:42 AM
An Intramuscular (IM) Bivalent Norovirus GI.1/GII.4 Virus Like Particle (VLP) Vaccine Protects Against Vomiting and Diarrhea in an Experimental Human GII.4 Oral Challenge Study
David I. Bernstein, MD, MA ; Robert L. Atmar, MD ; Marshall Lyon, MD ; John J. Treanor, MD ; Wilbur H. Chen, MD ; Robert Frenck, MD ; Xi Jiang, PhD ; Jan Vinje, PhD ; Mohamed S. Al-Ibrahim, MB, ChB ; Jill Barrett, MPH ; David Y. Graham, MD ; Charles Richardson, PhD ; Robert Goodwin, PhD ; Astrid Borkowski, MD ; Ralf Clemens, MD, PhD ; Paul M Mendelman, MD

10:54 AM
Reductions in Invasive and non-invasive pneumo-related US Hospital Admissions only Two Years after PCV13 Introduction: Evidence of Substantial Direct and Indirect (Herd) Benefits
Lone Simonsen, PhD ; Keith Klugman, MD, PhD, FIDSA ; Robert Taylor, PhD ; Cynthia Schuck, PhD ; Roger Lustig, BA ; Michael Haber, PhD

11:06 AM
Measles Outbreak among Members of the Orthodox Jewish Community —Brooklyn, New York, March-June 2013
Robert Arciuolo, MPH, CPH ; Tamara Brantley, MPH, CPH ; Rachel Jablonski ; Jie Fu, PhD ; Francesca R. Giancotti, PhD ; Jane Zucker, MD, MSc ; Jennifer Rosen, MD

11:18 AM
Lower Immunogenicity of HPV Vaccine in HIV-infected Girls aged 9-13 Years
Deborah Money, MD ; Erin Moses, MPH ; Simon Dobson, MD ; Jason C. Brophy, MD, MSc, DTM ; Sandra Blitz, MSc ; Sean Ari Bitnun, MD, MSc ; Lindy M. Samson, MD ; Normand Lapointe, MD ; Sharon Walmsley, MD, FRCP

11:30 AM
Tenofovir Disoproxil Fumarate as an Adjunctive Therapy for the Prevention of Vertical Transmission of Hepatitis B Virus Infection
Alper Gunduz ; Dilek Yildiz Sevgi ; Ahmet Sanli Konuklar ; Ahsen Oncul ; Nuray Uzun

11:42 AM
Therapeutic Use of an Oral Suspension of VP20621, Spores of a Non-Toxigenic Clostridium difficile (NTCD) Strain, for Prevention of Recurrence of C. difficile Infection (CDI)
Stephen Villano, MD ; John Armstrong, MD ; Thomas Meyer, MD ; Christine Lee, MD, FRCPC ; Michael Somero, MD ; Stuart Cohen, MD, FIDSA, FSHEA ; Uma Murthy, MD ; Andre Poirier, MD, MSc ; Trevor Van Schooneveld, MD ; Darrell Pardi, MD, MS ; Antonio Ramos, MD ; Michelle Barron, MD ; Dale Gerding, MD

11:54 AM
Evolving Epidemiology of New Delhi Metallo--Lactamase-Producing Enterobacteriaceae Reported in the United States
Alexander Kallen, MD, MPH ; J. Kamile Rasheed, PhD ; David Lonsway, MMSc ; Tatiana Travis, BS ; Alice Guh, MD, MPH ; Brandi Limbago, PhD ; Wendy Bamberg, MD

CME Credits:

ACPE Credits:

ACPE Number:

Disclosures:

K. Klugman, None

See more of: Oral Abstract Session

Findings in the abstracts are embargoed until 12:01 a.m. PST, Oct. 2nd with the exception of research findings presented at the IDWeek press conferences.